Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · August 15, 2022

A Study on the Effect of Canagliflozin in Japanese Patients With Type 2 Diabetes and Microalbuminuria: Rationale, Design, and Baseline Characteristics

Diabetes, Obesity & Metabolism

 

Additional Info

Diabetes, Obesity & Metabolism
Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study
Diabetes Obes Metab 2022 Aug 01;24(8)1429-1438, S Miyamoto, HJL Heerspink, D de Zeeuw, M Toyoda, D Suzuki, T Hatanaka, T Nakamura, S Kamei, S Murao, K Hida, S Ando, H Akai, Y Takahashi, D Koya, M Kitada, H Sugano, T Nunoue, A Nakamura, M Sasaki, T Nakatou, K Fujimoto, D Kawanami, T Wada, N Miyatake, M Yoshida, K Shikata

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading